SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of our study was to evaluate the clinical, diagnostic, therapeutic, and prognostic features of immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS).
methodsWe conducted a single-center retrospective case series of seven patients with IM3OS treated at Hospital del Mar between 2020 and 2025, together with a systematic review and descriptive patient-level synthesis of the published literature. PubMed/MEDLINE and Embase were searched for reports published between 2015 and 2025, following PRISMA 2020 guidelines. Eligible studies included case reports, case series, letters, correspondence, and conference abstracts providing sufficient individual patient-level data.
resultsIn our series, all seven patients were male, with a median age of 81 years. The most frequent tumor types were non-small cell lung cancer (NSCLC) (42.8%) and urothelial carcinoma (28.5%). Diplopia (71.4%), ptosis (71.4%), and dyspnea (71.4%) were the most common presenting manifestations. Most patients received high-dose corticosteroids (71.4%), intravenous immunoglobulins (85.7%), and additional non-steroidal immunosuppressive agents (85.7%). The systematic review included 71 studies and 103 patients. Median age was 71 years, and 68.9% were male. Melanoma (35.9%), renal cell carcinoma (16.5%), and NSCLC (16.5%) were the most frequent malignancies. Ptosis (71.8%) and weakness (62.1%) were the most common presenting symptoms. The most frequently reported initial regimen was methylprednisolone 1 g/day (35.9%), and 52.4% of patients received additional non-steroidal immunosuppressive agents.
conclusionIM3OS is a rare, early-onset, clinically severe immune-related overlap syndrome with a high mortality rate requiring prompt recognition, structured multisystem assessment, close cardiorespiratory monitoring, and multidisciplinary management. Current evidence remains observational and does not allow conclusions regarding therapeutic superiority.
Indexed as
Identifiers
42878911What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.